Ravindra Nidoni
Overview
Explore the profile of Ravindra Nidoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar P, Krishna P, Nidoni R, Adarsh C, Arun M, Shetty A, et al.
Am J Transplant
. 2024 Jan;
24(6):1087-1090.
PMID: 38219868
Atezolizumab plus bevacizumab is the preferred first-line treatment regimen for patients with advanced hepatocellular carcinoma. Limited data have shown promising results with the use of immune checkpoint inhibitors like nivolumab...
2.
Vijayashanker A, Chikkala B, Ghimire R, Nidoni R, Acharya M, Pandey Y, et al.
J Clin Exp Hepatol
. 2022 Jan;
12(1):29-36.
PMID: 35068782
Background: Natural portosystemic shunt ligation practices in liver transplant vary widely across transplant centres and are frequently undertaken to prevent the serious consequence of portal steal phenomenon. No concrete indications...
3.
Vijayashanker A, Chikkala B, Ghimire R, Nidoni R, Pandey Y, Dey R, et al.
Ann Hepatobiliary Pancreat Surg
. 2021 Aug;
25(3):328-335.
PMID: 34402432
Backgrounds/aims: Multiple ducts in right lobe living-donor liver transplant (LDLT) pose a technical challenge in biliary reconstruction. In the absence of separate recipient hepatic ducts for duct-to-duct anastomoses and certain...
4.
Nidoni R, Kandagaddala R, Agarwal S, Dey R, Chikkala B, Gupta S
J Clin Exp Hepatol
. 2021 Mar;
11(1):3-8.
PMID: 33679042
Background: With ageing population and higher prevalence of nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) in older patients, more and more living donor liver transplants (LDLTs) are being considered in...
5.
Nidoni R, Halder P, Nikhil S, R S, Kumar V
Indian J Surg Oncol
. 2020 Jun;
11(2):329-332.
PMID: 32523285
Gastrointestinal stromal tumours (GIST) are the most common gastrointestinal mesenchymal tumours of the gastrointestinal tract. They are diagnosed by the expression of markers like CD 117, CD 34, DOG-1 and...
6.
Vallabha T, Dhamangaonkar M, Sindgikar V, Nidoni R, Biradar H, Kv A, et al.
Indian J Surg
. 2017 Mar;
79(1):29-32.
PMID: 28331263
North Karnataka is one of the regions with the high prevalence of HIV+ individuals. Bijapur is a district in North Karnataka with high prevalence as per fact sheets of NACO...
7.
Vallabha T, Karjol U, Kalyanappagol V, Sindgikar V, Nidoni R, Biradar H, et al.
Indian J Surg
. 2016 May;
78(1):27-31.
PMID: 27186036
Oxygen supplemented at a concentration higher than 40-50 % for at least 2 h perioperatively is expected to reduce surgical site infections (SSI). Although supplementation of 80 % of oxygen...
8.
Nidoni R, Udachan T, Sasnur P, Baloorkar R, Sindgikar V, Narasangi B
J Clin Diagn Res
. 2016 Jan;
9(12):PC09-12.
PMID: 26816942
Introduction: Laparoscopic cholecystectomy (LC) is the gold standard treatment for symptomatic cholelithiasis. However, of all Laparoscopic cholecystectomies, 1-13% requires conversion to an open for various reasons. Thus, for surgeons it...
9.
Sasnur P, Nidoni R, Baloorkar R, Sindgikar V, Shankar B
J Clin Diagn Res
. 2014 Sep;
8(7):NR01-2.
PMID: 25177603
The treatment of infected necrotizing pancreatitis has evolved from time to time and the success of surgical intervention depends on the timing of necrosectomy. Bacterial infection occurs in 40-70% of...